In September 2025, Imexpharm’s profit before tax surged by 101%, while EBITDA increased by 48%. For the first nine months of 2025, the company’s gross and net...
Driven by a profound commitment to community well-being, the pharma industry is making bold strides forward, harnessing cutting-edge technologies and positioning ESG as...
With the Cat Khanh Pharmaceutical Factory Complex, Imexpharm and the rise of pharma industrial parks mark a new era for Vietnam’s pharmaceutical industry, elevating its...
The revised Pharmaceutical Law and strategic investments are paving the way for Imexpharm’s high growth in 2025, with a bold revenue target of approximately 3...
On April 18, 2025, Imexpharm announced Q1 business results, reporting net revenue of VND 594 billion and profit before tax of VND 95 billion, up 21% and 23%...
On November 19, 2024, Imexpharm Pharmaceutical Joint Stock Company was proudly recognized as the Top #1 Best Place to Work for 2024 in the Pharmaceutical, Medical...
Imexpharm leads breakthroughs in high-tech pharmaceutical production under the National Strategy, backed by the largest charter capital in the industry.
With a team of leading talents in the pharmaceutical industry, Imexpharm is driving a significant growth by boosting R&D as the strategy of developing high-tech...
Imexpharm Corporation (HoSE: IMP), which has the most production lines in Vietnam that follow EU-GMP requirements, may acquire an edge in the ethical drugs channel (ETC)...
After record profits and strong growth in 2023, the industry’s momentum faced limit ations in 2024 due to rising raw material costs and increased market competition.
Imexpharm’s achievement of being in the top 8% of domestic drug manufacturers meeting group 1 & 2 bidding standards in the ETC channel is a testament to its focus on...
Foreign enterprises are looking to collect shares of leading pharmaceutical companies in Việt Nam and become strategic shareholders.
VN
EN